

Running title: BATF2 reverse MDR in GC

BATF2 reverses multidrug resistance of gastric cancer cells and centrosome clustering by suppressing ATM phosphorylation

Wei Yang¹, Jianlin Song¹, Lixia Jiang¹, Wenchuan Zhu¹, Jianxun Wang¹, Qi Huang¹, Jiawei Hu¹, Rong Zeng^{2,*}, Bian Wu^{2,*}

¹Department of Gastrointestinal and Bariatric Metabolic Surgery, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China; ²Department of Medical Oncology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China

*Correspondence: rongzi2005146@163.com; wubian666888@sina.com

Received November 27, 2025 / Accepted April 20, 2026

Chromosome instability (CIN) is a major contributor to drug resistance and recurrence. As a crucial mechanism of CIN, centrosome clustering has emerged as a promising therapeutic strategy. However, the roles and regulatory mechanisms of centrosome clustering in gastric cancer remain unclear. BATF2 was previously identified as a key modulator of multidrug resistance (MDR) in gastric cancer (GC). To examine the involvement of centrosome clustering in the mechanism by which BATF2 reverses MDR in GC, adriamycin (ADR)- and vincristine (VCR)-resistant cell lines, NCI-N87/ADR and NCI-N87/VCR, were used for investigations. Expression of BATF2 was downregulated in both drug-resistant cells, particularly in NCI-N87/ADR cells. Cells with BATF2 knockdown exhibited higher cell viability and lower apoptosis rates, and such changes were reversed by BATF2 overexpression. The enhanced centrosome clustering in cells transfected with sh-BATF2 was accompanied by increased KIFC1 expression, which was inhibited after BATF2 overexpression. BATF2 reversed MDR and inhibited centrosome clustering by inhibiting ATM phosphorylation, which was evidenced by ATM overexpression. Meanwhile, KU-60019, a specific inhibitor of ATM, could markedly reverse the pro-tumor effects of BATF2 knockdown. In conclusion, BATF2 is a potential target for reversing MDR in GC, and targeting KIFC1-related centrosome clustering by suppressing ATM phosphorylation is proposed as a key mechanism.

Key words: gastric cancer; multidrug resistance; centrosome clustering; BATF2

Gastric cancer (GC) is a malignancy originating from gastric mucosal epithelium [1]. Global Cancer Statistics estimate that GC is the fifth leading cause of both cancer incidence and cancer-related deaths worldwide, with 968,350 newly diagnosed GC cases (4.9% of all new cases) and 659,853

GC-caused deaths (6.8% of all cancer-related deaths) in 2022 [2]. Treatment options for GC depend primarily on the stage of the disease at the time of presentation, but most patients are seen at an advanced stage and require pharmacotherapy, mainly chemotherapy [3]. Conventional chemotherapeutics comprises of cisplatin, epirubicin, paclitaxel and 5-fluorouracil. Nevertheless, the 5-year overall survival rate for GC remains below 30% because of limited curative effect of chemotherapy [4]. Although chemotherapy drugs have continued to advance over the past few years, improving survival outcomes for patients with advanced GC, progress has reached a bottleneck [5, 6]. The main reason is that GC cells develop multidrug resistance (MDR), which leads to reduced sensitivity to chemotherapy [1, 7, 8]. Therefore, identifying methods to reverse MDR clinically and improve chemotherapy efficacy has become a focal point and a challenge in current research.

Mounting evidence suggests that the MDR mechanism of GC is closely related to chromosomal instability (CIN) abnormalities [9, 10]. CIN is widely recognized as a hallmark of tumors [11], including GC, and is positively associated with treatment resistance, poor clinical outcomes, immune evasion, and a high risk of recurrence and metastasis [12, 13]. Whereas CIN usually exhibits centrosome amplification [14, 15], and to avoid multipolar spindles and cell death, cancer cells achieve bipolar division by inducing supernumerary centrosome clustering, an adaptive survival strategy that allows cancer cells to divide successfully despite bearing supernumerary centrosomes [15, 16]. As a crucial mechanism of CIN, centrosome clustering has been proposed as a promising target for therapeutic intervention of human cancers [17, 18]. Nevertheless, the regulatory mechanisms of centrosome clustering and functions of centrosome clustering remain largely unclear.

Kinesin Family Member C1 (KIFC1) is a novel driver protein and centrosome clustering regulator participating in extra centrosome clustering in tumor cells [16, 19]. Elevated expression of KIFC1 has been observed in GC tissues [20], and its high expression is linked to a worse clinical outcome [21, 22]. KIFC1 knockdown could repress the sphere formation of GC cells, indicating the close involvement of KIFC1 in GC stem cells [20]. In addition, KIFC1 mediates the resistance to drugs, such as docetaxel [23] and cisplatin [24] in other cancers. However, whether KIFC1 mediates MDR of GC cells, and the associations between its functions and centrosome clustering in GC, have not been reported in GC.

Basic Leucine Zipper ATF-Like Transcription Factor 2 (BATF2), also termed SARI, has been

recognized as a novel tumor suppressor in human tumors [25-27]. In GC, Xie et al. demonstrate that reduced BATF2 expression in GC tissues is linked to peritoneal recurrence post-curative gastrectomy, and that GC growth and metastasis can be restrained by enhancing BATF2 expression [28]. Our previous studies have demonstrated the important role of BATF2 in reversing MDR and inhibiting chemotherapy resistance in GC [29-31]. However, whether BATF2 regulates centrosome clustering and thus affects the mechanism of MDR in GC remains unknown. To address this issue, we conducted the current study to elucidate the possible linkages among BATF2, centrosome clustering and MDR in GC based on two MDR cell models. This study may provide novel insights to illustrate the mechanism of MDR in GC.

Materials and Methods

Establishment of drug-resistant cells. GC cell line NCI-N87 from Wuhan Procell Life Technology Co., LTD. (#CL-0169, China) was maintained in RPMI-1640 medium bearing an additional adding of 10% FBS (#16140071, Gibco) and 1% penicillin-streptomycin under the conditions of 5% CO₂ at 37 °C. Adriamycin (ADR, #A864033, Macklin, Shanghai, China) and Vincristine (VCR, #V861369, Macklin)-resistant cells, NCI-N87/ADR and NCI-N87/VCR, were acquired via enhancing drug dose gradually as previously described [32-34]. For the culture of drug-resistant cells, a final concentration of 0.5 mg/mL ADR and 1 mg/mL VCR was used to maintain the drug-resistant phenotype.

Cell transfection. Lentiviral vector system was employed to overexpress BATF2 and ataxia-telangiectasia mutated (ATM) or to knockdown BATF2. Based on DSIR website (<http://biodev.cea.fr/DSIR/>), we designed short hairpin RNA (shRNA) against BATF2: 5'-ACACTATGTTAGTATCTAA-3' (sense), and 5'-ACACTATGTTAGTATCTAA-3' (antisense). From NCBI database, we retrieved sequences of mature BATF2 and ATM. Subsequently, we transfected vectors bearing sh-BATF2, BATF2, ATM as well as matching (negative control) NC sequences into 293T cells, along with the packaging plasmids (pMDLg/pRRE: pVSV-G: pRSV-Rev=5:3:2) with the aids of HighGene reagent, followed by collecting and concentrating lentivirus particles 48h after transfection. For lentiviral infection, NCI-N87/ADR and NCI-N87/VCR cells (1×10^5 /ml) were inoculated into 6-well plates, and lentivirus (1×10^8 TU/ml) was added to the medium at 70-90% confluency. Following 48 h post-infection, 2.5 µg/ml

105 puromycin was added to select stably transfected cells.

106 **qRT-PCR.** Total RNAs isolation from cells were conducted with the aids of TRIzol reagent
 107 (#15596018, Invitrogen). The isolated RNAs were reversely transcribed into cDNA using FastKing
 108 RT SuperMix (#KR118-02, TIANGEN), followed by PCR amplification with the aids of SYBR
 109 Green PCR Master Mix (#A4004M, Lifeint). The used primers are: BATF2-F:
 110 5'-GCTCCTGTGGGCAAGAGAAT-3'; BATF2-R: 5'-AGAGAGCAGGTTTGTGCTCC-3';
 111 GAPDH-F: 5'-CCATGGGGAAGGTGAAGGTC-3'; GAPDH-R: 5'-
 112 AGTGATGGCATGGACTGTGG-3'.

113 **Western blot.** After cell lysis with RIPA, concentration of cell proteins was determined with the
 114 aids of BCA assay kit. Proteins were separated, transferred onto PVDF membranes, followed by
 115 incubation with antibodies BATF2 (#PA5-103647, Thermo), anti-KIFC1 (#12313, CST), anti-ATM
 116 (#2873, CST) and anti-phosphorylated ATM (p-ATM, #5883, CST) overnight at 4 °C. Secondary
 117 antibodies incubation was then carried out for 60 min at dark. The blotting bands were washed by
 118 ECL reagent and were packaged using a cling film, and were transferred to cassette for film
 119 exposure.

120 **Immunofluorescence.** Immunofluorescence was performed according to the methods in previous
 121 studies. In brief, cells were re-suspended into a 12-well plate containing cell sliver, and were treated
 122 with ADR or VCR for 24 h. After cell fixation, permeabilization and blocking, anti- α -tubulin and
 123 anti-centrin-2 were added to incubate with cells overnight at 4 °C. Afterwards, IgG H&L (Alexa
 124 Fluor® 647) secondary antibody incubation and DAPI staining were carried out. Finally, sections
 125 were canned on a laser scanning confocal microscope after sealed with fluorescent quenching
 126 sealant.

127 **CCK-8 assay.** Cells were placed in 96-well plates (2,000 cells/well), and were treated with ADR or
 128 VCR. After 24 h of treatment, 10 μ l CCK-8 was added to each well for 2 h to calculate the cell
 129 counts on the basis of the optical density at 450 nm.

130 **Flow cytometry (FCM).** Apoptosis was determined using an Annexin V-FITC apoptosis kit
 131 (#C1062S, Beyotime). Briefly, after digested with 0.25% EDTA-free Tyrisin, cells were collected
 132 by centrifugation. Then, cells were washed by pre-cooled PBS and were resuspended in 300 μ l
 133 binding Buffer, followed by incubation with 5 μ l Annexin V-FITC and 10 μ l of propidium iodide in
 134 dark. The cells were analyzed by an CytoFLEX S FCM (Beckman Coulter Life Sciences, USA),

135 and were analyzed using CELL Quest software.

136 **Co-Immunoprecipitation (Co-IP).** To explore the interaction between BATF2 and ATM, we
137 conducted Co-IP assay according to the manual of the rProtein A/G Magnetic IP/Co-IP Kit
138 (#abs9649, absin). Briefly, cells were collected and washed by PBS, and then were lysed in 1x
139 Lysis/Wash Buffer (Enhanced) on ice. After centrifugation at $14,000 \times g$, $4^{\circ}C$ for 10 min, the
140 supernatant was collected, and was precleared with protein A/G beads for 2 h before incubation
141 with primary antibodies: anti-ATM (#16592-1-AP, Proteintech) and anti-BATF2 (#16592-1-AP,
142 Proteintech). Isotype immunoglobulin G (IgG) antibody was used as negative control. Afterwards,
143 Protein A/G MagPoly Beads were added to the immunoprecipitation mixture and rotated for 30 min.
144 Afterwards, the immunoprecipitated protein complexes were washed with Elution buffer, and the
145 resulting supernatants were collected, and Neutralization Buffer was added. Finally, the collected
146 supernatants were detected by Western blot.

147 **Statistical analysis.** All experiments were conducted with three repetitions. Data presenting in the
148 form of mean $\pm$ standard deviation was employed for statistics. Data for changes on cell viability
149 along with the drug dosages was compared by two-way RM ANOVA. ANOVA coupled a Tukey's
150 post hoc test was employed for statistics of other data. $P < 0.05$ denotes statistical difference.

152 Results

153 **BATF2 overexpression enhances susceptibility of NCI-N87 cells to ADR and VCR.** Expression
154 of BATF2 was detected in drug-resistant cells: NCI-N87/ADR and NCI-N87/VCR. Compared with
155 that in NCI-N87 cells, significant decrease in its protein expression was observed in these two
156 drug-resistant cells, particularly in NCI-N87/ADR cells (Figure 1A). To elucidate the exact roles of
157 BATF2 expression in MDR, we first established BATF2 overexpression or knockdown model in
158 NCI-N87/ADR and NCI-N87/VCR cells (Figure 1B). Subsequently, cell viability was determined
159 using the CCK-8 assay, and we found that BATF2 overexpression exhibited enhanced
160 chemosensitivity (low cell viability) to ADR and VCR than matched NC group. Cells with BATF2
161 knockdown showed highest cell viability, indicating that BATF2 knockdown decreased
162 susceptibility to ADR and VCR (Figure 1C). Consistently, FCM analysis indicated that in two
163 drug-resistant cells, BATF2 overexpression exhibited highest apoptosis rate, whereas BATF2
164 knockdown exhibited lowest apoptosis rate (Figures 1D, 1E). All these results suggest that BATF2

inhibition promotes MDR, while BATF2 overexpression sensitizes NCI-N87 cells to chemotherapy.

BATF2 overexpression inhibits KIFC1 expression and centrosome clustering. KIFC1 is a centrosome clustering molecule that prevents cancer cells from undergoing centrosome-amplification-induced apoptosis [35]. We found that expression of KIFC1 was markedly reduced in NCI-N87/ADR and NCI-N87/VCR cells with BATF2 overexpression, whereas KIFC1 expression was observably enhanced in NCI-N87/ADR and NCI-N87/VCR cells with BATF2 knockdown (Figure 2A). Centrosome clustering was further observed by immunofluorescence staining. As shown in (Figure 2B), ratio of centrosome clustering was high in cells with BATF2 knockdown in comparison with corresponding NC. After BATF2 overexpression, the ratio of centrosome clustering significant decreased. Similar results were also observed in NCI-N87/VCR cells (Figure 2B).

BATF2 overexpression inhibits the elevated p-ATM in drug-resistant cells. Expression of ATM and p-ATM was determined, and we found that compared with NCI-N87 cells, the drug-resistant NCI-N87/ADR and NCI-N87/VCR cells showed markedly elevated level of p-ATM, particularly in NCI-N87/ADR cells (Figure 3A). To investigate the possible interaction between BATF2 and ATM, we conducted Co-IP assay. The results indicated that BATF2 and ATM were co-precipitated with each other (Figure 3B), suggesting that BATF2 could directly interact with ATM. Besides, in both NCI-N87/ADR and NCI-N87/VCR cells, BATF2 overexpression could significantly reduce the level of p-ATM, while BATF2 knockdown could elevate p-ATM level in drug-resistant cells (Figure 3C). These results suggested that p-ATM level was increased in multidrug-resistant NCI-N87 cells, and such increased p-ATM level could be inhibited by BATF2 overexpression.

BATF2 mediates chemosensitivity and centrosome clustering by inhibiting p-ATM. To validation whether ATM involving in the actions of BATF2-mediated chemosensitivity, we further overexpressed ATM in BATF2-overexpressed multidrug-resistant NCI-N87 cells. ATM overexpression showed no influences on the expression of BATF2 (Figure 4A). BATF2 overexpression could significantly reduce the level of p-ATM/ATM, while such decrease could be partly reversed following ATM overexpression (Figure 4A). BATF2 overexpression exhibited enhanced chemosensitivity (lower cell viability and higher cells apoptosis) to ADR and VCR than matched NC group, and such susceptibility was partly reversed following ATM overexpression (Figures 4B, 4C). Moreover, overexpression of ATM elevated the reduced KIFC1 and reduced ratio

195 of centrosome clustering caused by BATF2 overexpression in both NCI-N87/ADR and
196 NCI-N87/VCR cells (Figures 5A, 5B). Meanwhile, 3 μ M KU-60019 (#Y242876, Beyotime), a
197 specific inhibitor of ATM, was used to inhibit ATM in cells with BATF2 knockdown. As expected,
198 KU-60019 treatment markedly reduced the increased level of p-ATM/ATM caused by BATF2
199 knockdown in both two cells (Figure 6A). In addition, BATF2 knockdown observably promoted
200 cells viability (Figure 6B) and inhibited cell apoptosis (Figure 6C), while such effects of BATF2
201 knockdown were markedly reversed after KU-60019 treatment (Figures 6B, 6C). Altogether, these
202 findings suggested that BATF2 could mediate chemosensitivity and centrosome clustering by
203 inhibiting p-ATM.

204

205 Discussion

206 Although chemotherapy can prolong the survival of patients with advanced GC, the overall survival
207 rate is still not ideal. MDR is the primary factor that limits the therapeutic effect of chemotherapy
208 and leads to the death of patients [36, 37]. CIN is one of the main features of solid tumors, including
209 GC, and has been demonstrated to contribute to the therapeutic resistance in cancer treatment [38,
210 39]. Although CIN is a feature of GC [40], centrosome clustering, a contributor to CIN, has not
211 been reported in GC, especially its relationship with MDR in GC.

212 The centrosome is the primary microtubule-organizing center, which ensures the symmetry and
213 bipolarity of cell division by establishing bipolar spindle; this function is essential for accurate cell
214 mitosis [18]. Unlike normal cells, cancer cells often exhibit supernumerary centrosomes, called
215 centrosome amplification, which is a hallmark of cancer and is strongly associated with tumor
216 progression, poor clinical outcomes, and multiple carcinogenic phenotypes, such as aneuploidy [41].
217 For cancer cells with supernumerary centrosomes, to avoid the emergence of multiple spindles that
218 can trigger cell death, cancer cells usually achieve pseudo-bipolar division by centrosome clustering
219 to form pseudo-bipolar spindles, thus ensuring cell survival, which is an adaptive survival
220 mechanism of tumor cells [42, 43]. Therefore, targeting centrosome clustering may be a promising
221 therapeutic strategy, and understanding the processes that control centrosome clustering is crucial
222 for this strategy. In this study, we found that overexpression of BATF2 not only inhibited the
223 supernumerary centrosomes clustering, but also reduced cell viability and increased apoptosis of
224 both NCI-N87/ADR and NCI-N87/VCR cells, possibly due to the induction of multipolar division.

225 The results of this study emphasize the involvement of centrosome clustering in MDR, and
226 targeting centrosomes clustering may enhance the sensitivity to chemotherapeutics.

227 KIFC1 has recently been recognized as centrosome clustering molecule, which is fundamental for
228 viability of tumor cells bearing supernumerary centrosome [16, 44]. Specifically, KIFC1 allows
229 tumor cells bearing multiple centrosomes to survive cell division, which is not necessary for normal
230 somatic cells, but is necessary for normal division in tumor cells bearing supernumerary
231 centrosomes [45, 46]. The loss of KIFC1 could cause death of tumor cells by inducing deadly
232 multipolar division, but no influence was observed for the division of normal cells possessing two
233 centrosomes [47]. Expression of KIFC1 was found to be up-regulated in GC tissues [21], and its
234 enhanced expression was strongly linked to lymph node/distant metastasis, depth of invasion, TNM
235 stage, tumor size and a worse survival in GC [22]. Hence, KIFC1 suppression is proposed as an
236 available strategy to for GC treatment. In this study, we found that expression of KIFC1 was
237 elevated in both ADR and VCR-resistant GC cell lines, and such elevated expression could be
238 markedly reduced after BATF2 overexpression, accompanied by a decrease in the number of cells
239 with centrosome clustering. The cooccurrence of KIFC1 dysregulation with centrosome clustering
240 suggests that targeting KIFC1 might be an available strategy to modulate centrosome clustering.

241 BATF2, a transcription factor of bZIP family, has been reported to participate in the progression of a
242 wide variety of human cancers. Particularly, BATF2 exerts as a tumor suppressor, and its high level
243 is frequently associated with an inhibition of tumor growth and metastasis [25, 48-52]. In GC,
244 BATF2 expression was reduced in GC tissues [28]. Such reduced BATF2 expression in GC showed
245 correlations with a worse survival outcome and stem cell-like properties, and enhanced BATF2
246 level was linked to an increased responsiveness to 5-Fluorouracil and an improved outcomes of GC
247 patients who received postoperative chemotherapy [53]. In terms of mechanism, BATF2 was found
248 to inhibit drug transporter ABCG2 and to inhibit AKT phosphorylation while promote PTEN
249 stability [53]. In previous studies [29-31], we investigated the functional roles and the underlying
250 mechanisms of BATF2 in GC MDR cells, and found that it can reverse MDR through decreasing
251 P-glycoprotein (P-gp, an ABC transporter) mediated drug efflux via inhibiting AP-1 [29] or
252 Wnt/ β -catenin signaling [30], or through inhibiting Drp1-dependent mitochondrial fission via
253 p53/ERK pathway in GC [31]. In this study, we found that BATF2 could reverse MDR and inhibit
254 KIFC1-mediated centrosome clustering by inhibiting p-ATM *in vitro*. Consistently, a previous study

also revealed the regulatory roles of ATM kinases on centrosome clustering [46]. ATM kinase is a key protein that is frequently recruited and activated in DNA damage response (DDR) pathway to trigger cell cycle arrest and promote DNA repair [54]. DDR defect is an established driver and hallmark of cancers, and the activation of ATM in DDR pathway is found to be benefits for abnormal cell survival [54]. Through the autophosphorylation at Ser1981, ATM modulates the cellular responses to DNA double-strand breaks [55]. p-ATM was observed to be elevated in drug-resistant NCI-N87/ADR and NCI-N87/VCR cells, and such enhanced p-ATM level could be inhibited after BATF2 overexpression. The possible mechanism by which overexpression of BATF2 reverses MDR in GC cells has been summarized in Figure 7. These results indicated that BATF2 could target KIFC1-related centrosome clustering by suppressing p-ATM, thus enhancing the chemosensitivity of GC cells to VCR and ADR. This study broadens our understanding of the mechanism of BATF2 in MDR in GC, and contributes to the translational feasibility of BATF2 in GC.

Limitations and prospects: Although this study demonstrated the role of BATF2 in reversing MDR of GC cells to VCR and ADR by inhibiting KIFC1-mediated centrosome clustering, whether KIFC1-mediated centrosome clustering is involved in resistance of GC cells to other chemotherapeutics is largely unclear, and this should be investigated in future studies. In addition, our results suggest that ATM positively regulates KIFC1 as a downstream of BATF2, and ATM can reverse the inhibitory effects of BATF2 on KIFC1. However, it is not yet clear whether ATM regulates KIFC1 at the transcriptional level or the protein level, and this will be investigated in our subsequent studies. Besides, a previous study indicated that expression of BATF2 showed close linkage with infiltration of activated CD4⁺ memory T cells, and the signature based on CD36-BATF2/MYB could be used as an indicator for predicting the response to anti-PD-1 immunotherapy [56]. Li et al. [57] observed upregulated expression of PD-L1 in GC MKN-45 cells with BATF2 knockdown, indicating the potential of BATF2 as a biomarker for predicting the efficacy of PD-L1 blockade therapy in GC. Therefore, whether BATF2 mediates the sensitivity of GC cells to immune checkpoint blockade therapy should also be investigated in future studies. Finally, *in vivo* validation should be conducted in our future investigations to strengthen the reliability and translational value of this study.

In summary, this study demonstrated that centrosome clustering existed in MDR GC cells. BATF2

overexpression could inhibit cell viability, centrosome clustering and KIFC1 expression, while induce apoptosis in NCI-N87/ADR and NCI-N87/VCR cells. We proposed that BATF2 could reverse MDR in GC cells and inhibit KIFC1-mediated centrosome clustering via inhibiting p-ATM. This study provided a new perspective on the mechanism by which BATF2 reverses MDR in GC.

Acknowledgements: This work was supported by Co-operation Fund of Kunming Medical University and the Science and Technology Department of Yunnan Province (grant number 202301AY070001-63), Beijing Science And Technology Innovation Medical Development Foundation (grant number KC2023-JX-0186-FZ095) and Yunnan Provincial Department of Science and Technology-Major Science and Technology Special Project Plan of Yunnan Province Biomedical and Health Industry Promotion Center (grant number 202402AA310006).

References

- [1] LIU J, YUAN Q, GUO H, GUAN H, HONG Z et al. Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives. *Biomed Pharmacother* 2024; 173: 116310. <https://doi.org/10.1016/j.biopha.2024.116310>
- [2] BRAY F, LAVERSANNE M, SUNG H, FERLAY J, SIEGEL RL et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2024; 74: 229-263. <https://doi.org/10.3322/caac.21834>
- [3] GUAN WL, HE Y, XU RH. Gastric cancer treatment: recent progress and future perspectives. *J Hematol Oncol* 2023; 16: 57. <https://doi.org/10.1186/s13045-023-01451-3>
- [4] WANG G, HUANG Y, ZHOU L, YANG H, LIN H et al. Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer. *Crit Rev Oncol Hematol* 2024; 198: 104197. <https://doi.org/10.1016/j.critrevonc.2023.104197>
- [5] SMYTH EC, NILSSON M, GRABSCH HI, VAN GRIEKEN NC, LORDICK F. Gastric cancer. *Lancet* 2020; 396: 635-648. [https://doi.org/10.1016/s0140-6736\(20\)31288-5](https://doi.org/10.1016/s0140-6736(20)31288-5)
- [6] LI K, ZHANG A, LI X, ZHANG H, ZHAO L. Advances in clinical immunotherapy for gastric cancer. *Biochim Biophys Acta Rev Cancer* 2021; 1876: 188615. <https://doi.org/10.1016/j.bbcan.2021.188615>
- [7] CHE G, YIN J, WANG W, LUO Y, CHEN Y et al. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics. *Drug Resist Updat* 2024; 74: 101080. <https://doi.org/10.1016/j.drug.2024.101080>
- [8] ZHOU Y, CHEN Y, SHI Y, WU L, TAN Y et al. FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway. *J Clin Invest* 2023; 133: e158705. <https://doi.org/10.1172/jci158705>
- [9] LUKOW DA, SHELTER JM. Chromosomal instability and aneuploidy as causes of cancer drug resistance. *Trends Cancer* 2022; 8: 43-53. <https://doi.org/10.1016/j.trecan.2021.09.002>

- 323 [10] LUKOW DA, SAUSVILLE EL, SURI P, CHUNDURI NK, WIELAND A et al.
 324 Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies. *Dev*
 325 *Cell* 2021; 56: 2427-39.e4. <https://doi.org/10.1016/j.devcel.2021.07.009>
- 326 [11] DREWS RM, HERNANDO B, TARABICHI M, HAASE K, LESLUYES T et al. A
 327 pan-cancer compendium of chromosomal instability. *Nature* 2022; 606: 976-983.
 328 <https://doi.org/10.1038/s41586-022-04789-9>
- 329 [12] BAKHOUM SF, CANTLEY LC. The Multifaceted Role of Chromosomal Instability in
 330 Cancer and Its Microenvironment. *Cell* 2018; 174: 1347-1360.
 331 <https://doi.org/10.1016/j.cell.2018.08.027>
- 332 [13] CHEN X, AGUSTINUS AS, LI J, DIBONA M, BAKHOUM SF. Chromosomal instability
 333 as a driver of cancer progression. *Nat Rev Genet* 2025; 26: 31-46.
 334 <https://doi.org/10.1038/s41576-024-00761-7>
- 335 [14] PIEMONTE KM, ANSTINE LJ, KERI RA. Centrosome Aberrations as Drivers of
 336 Chromosomal Instability in Breast Cancer. *Endocrinology* 2021; 162: bqab208.
 337 <https://doi.org/10.1210/endocr/bqab208>
- 338 [15] KRÄMER A, MAIER B, BARTEK J. Centrosome clustering and chromosomal (in)stability:
 339 a matter of life and death. *Mol Oncol* 2011; 5: 324-335.
 340 <https://doi.org/10.1016/j.molonc.2011.05.003>
- 341 [16] MAROTTA VE, SABAT-POŚPIECH D, FIELDING AB, PONSFORD AH, THOMAZ A et al.
 342 OTUD6B regulates KIFC1-dependent centrosome clustering and breast cancer cell
 343 survival. *EMBO Rep* 2025; 26: 1003-1035. <https://doi.org/10.1038/s44319-024-00361-w>
- 344 [17] GODINHO SA, KWON M, PELLMAN D. Centrosomes and cancer: how cancer cells
 345 divide with too many centrosomes. *Cancer Metastasis Rev* 2009; 28: 85-98.
 346 <https://doi.org/10.1007/s10555-008-9163-6>
- 347 [18] FIRDOUS F, RAZA HG, CHOTANA GA, CHOUDHARY MI, FAISAL A et al. Centrosome
 348 Clustering & Chemotherapy. *Mini Rev Med Chem* 2023; 23: 429-451.
 349 <https://doi.org/10.2174/1389557522666220820113953>
- 350 [19] ZHANG C, WU BZ, DI CIANO-OLIVEIRA C, WU YF, KHAVKINE BINSTOCK SS et al.
 351 Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome
 352 amplification. *Cancer Gene Ther* 2024; 31: 1559-1570.
 353 <https://doi.org/10.1038/s41417-024-00824-1>
- 354 [20] OUE N, MUKAI S, IMAI T, PHAM TT, OSHIMA T et al. Induction of KIFC1 expression in
 355 gastric cancer spheroids. *Oncol Rep* 2016; 36: 349-355.
 356 <https://doi.org/10.3892/or.2016.4781>
- 357 [21] CAO FY, ZHENG YB, YANG C, HUANG SY, HE XB et al. miR-635 targets KIFC1 to
 358 inhibit the progression of gastric cancer. *J Investig Med* 2020; 68: 1357-1363.
 359 <https://doi.org/10.1136/jim-2020-001438>
- 360 [22] JUNG J, JEONG H, CHOI JW, KIM HS, OH HE et al. Increased expression levels of
 361 AURKA and KIFC1 are promising predictors of progression and poor survival associated
 362 with gastric cancer. *Pathol Res Pract* 2021; 224: 153524.
 363 <https://doi.org/10.1016/j.prp.2021.153524>
- 364 [23] SEKINO Y, OUE N, KOIKE Y, SHIGEMATSU Y, SAKAMOTO N et al. KIFC1 Inhibitor
 365 CW069 Induces Apoptosis and Reverses Resistance to Docetaxel in Prostate Cancer. *J Clin*
 366 *Med* 2019; 8: 225. <https://doi.org/10.3390/jcm8020225>

- [24] GAO H, WANG J, LIU J, WANG H, WANG T et al. FOXD1 activates KIFC1 to modulate aerobic glycolysis and reinforce cisplatin resistance of breast cancer. *Reprod Biol* 2025; 25: 100969. <https://doi.org/10.1016/j.repbio.2024.100969>
- [25] ZHANG X, LIU Y, DAI L, SHI G, DENG J et al. BATF2 prevents glioblastoma multiforme progression by inhibiting recruitment of myeloid-derived suppressor cells. *Oncogene* 2021; 40: 1516-1530. <https://doi.org/10.1038/s41388-020-01627-y>
- [26] ZHOU J, LEI Z, CHEN J, LIAO S, CHEN Y et al. Nuclear export of BATF2 enhances colorectal cancer proliferation through binding to CRM1. *Clin Transl Med* 2023; 13: e1260. <https://doi.org/10.1002/ctm2.1260>
- [27] HAN T, WANG Z, YANG Y, SHU T, LI W et al. The tumor-suppressive role of BATF2 in esophageal squamous cell carcinoma. *Oncol Rep* 2015; 34: 1353-1360. <https://doi.org/10.3892/or.2015.4090>
- [28] XIE JW, HUANG XB, CHEN QY, MA YB, ZHAO YJ et al. m(6)A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling. *Mol Cancer* 2020; 19: 114. <https://doi.org/10.1186/s12943-020-01223-4>
- [29] YANG W, ZHAO S, WU B, XU J, WU Z et al. BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells. *Cancer Chemother Pharmacol* 2019; 84: 1279-1288. <https://doi.org/10.1007/s00280-019-03958-4>
- [30] YANG W, WU B, MAN N, WANG Y, GUO J et al. BATF2 reverses multidrug resistance of human gastric cancer cells by suppressing Wnt/ β -catenin signaling. *In Vitro Cell Dev Biol Anim* 2019; 55: 445-452. <https://doi.org/10.1007/s11626-019-00360-5>
- [31] YANG W, ZENG R, SONG J, MAN N, ZHU W et al. Drp1-Dependent Mitochondrial Fission is Involved in Adriamycin Resistance in Gastric Cancer Cells: A Perspective from the BATF2/p53/ERK Regulatory Axis. *Tohoku J Exp Med* 2025. <https://doi.org/10.1620/tjem.2025.J091>
- [32] WANG S, CHEN W, YU H, SONG Z, LI Q et al. lncRNA ROR Promotes Gastric Cancer Drug Resistance. *Cancer Control* 2020; 27: 1073274820904694. <https://doi.org/10.1177/1073274820904694>
- [33] TRAVERSO N, RICCIARELLI R, NITTI M, MARENGO B, FURFARO AL et al. Role of glutathione in cancer progression and chemoresistance. *Oxid Med Cell Longev* 2013; 2013: 972913. <https://doi.org/10.1155/2013/972913>
- [34] LI DQ, WANG ZB, BAI J, ZHAO J, WANG Y et al. Reversal of multidrug resistance in drug-resistant human gastric cancer cell line SGC7901/VCR by antiprogesterone drug mifepristone. *World J Gastroenterol* 2004; 10: 1722-1725. <https://doi.org/10.3748/wjg.v10.i12.1722>
- [35] JINNA N, YUAN YC, RIDA P. Kinesin Family Member C1 (KIFC1/HSET) Underlies Aggressive Disease in Androgen Receptor-Low and Basal-Like Triple-Negative Breast Cancers. *Int J Mol Sci* 2023; 24: 16072. <https://doi.org/10.3390/ijms242216072>
- [36] WANG J, HUANG Q, HU X, ZHANG S, JIANG Y et al. Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer. *Cancer Res* 2022; 82: 1503-1517. <https://doi.org/10.1158/0008-5472.Can-21-1820>
- [37] HU X, MA Z, XU B, LI S, YAO Z et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. *Cancer Commun (Lond)* 2023; 43: 909-937. <https://doi.org/10.1002/cac2.12459>

- 411 [38] PANCIONE M, CERULO L, REMO A, GIORDANO G, GUTIERREZ-UZQUIZA Á et al.
 412 Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process.
 413 *Biomolecules* 2021; 11: 629. <https://doi.org/10.3390/biom11050629>
- 414 [39] SANSREGRET L, VANHAESEBROECK B, SWANTON C. Determinants and clinical
 415 implications of chromosomal instability in cancer. *Nat Rev Clin Oncol* 2018; 15: 139-150.
 416 <https://doi.org/10.1038/nrclinonc.2017.198>
- 417 [40] CHEN Z, ZHANG C, ZHANG M, LI B, NIU Y et al. Chromosomal instability of circulating
 418 tumor DNA reflect therapeutic responses in advanced gastric cancer. *Cell Death Dis* 2019;
 419 10: 697. <https://doi.org/10.1038/s41419-019-1907-4>
- 420 [41] SAATCI O, AKBULUT O, CETIN M, SIKIRZHYTSKI V, UNER M et al. Targeting
 421 TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome
 422 amplification. *Cell Death Differ* 2023; 30: 1305-1319.
 423 <https://doi.org/10.1038/s41418-023-01140-1>
- 424 [42] KALKAN BM, OZCAN SC, CICEK E, GONEN M, ACILAN C. Nek2A prevents
 425 centrosome clustering and induces cell death in cancer cells via KIF2C interaction. *Cell*
 426 *Death Dis* 2024; 15: 222. <https://doi.org/10.1038/s41419-024-06601-0>
- 427 [43] MASHIMA Y, NOHIRA H, SUGIHARA H, DYNLACHT BD, KOBAYASHI T et al. KIF24
 428 depletion induces clustering of supernumerary centrosomes in PDAC cells. *Life Sci Alliance*
 429 2022; 5: e202201470. <https://doi.org/10.26508/lsa.202201470>
- 430 [44] SHARMA N, SETIAWAN D, HAMELBERG D, NARAYAN R, ANEJA R. Computational
 431 benchmarking of putative KIFC1 inhibitors. *Med Res Rev* 2023; 43: 293-318.
 432 <https://doi.org/10.1002/med.21926>
- 433 [45] RATH O, KOZIELSKI F. Kinesins and cancer. *Nat Rev Cancer* 2012; 12: 527-539.
 434 <https://doi.org/10.1038/nrc3310>
- 435 [46] FAN G, SUN L, MENG L, HU C, WANG X et al. The ATM and ATR kinases regulate
 436 centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation. *Nat*
 437 *Commun* 2021; 12: 20. <https://doi.org/10.1038/s41467-020-20208-x>
- 438 [47] KWON M, GODINHO SA, CHANDHOK NS, GANEM NJ, AZIOUNE A et al.
 439 Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. *Genes*
 440 *Dev* 2008; 22: 2189-2203. <https://doi.org/10.1101/gad.1700908>
- 441 [48] LIU J, LI J, TUO Z, HU W, LIU J. BATF2 inhibits PD-L1 expression and regulates CD8+
 442 T-cell infiltration in non-small cell lung cancer. *J Biol Chem* 2023; 299: 105302.
 443 <https://doi.org/10.1016/j.jbc.2023.105302>
- 444 [49] WEN H, TANG J, CUI Y, HOU M, ZHOU J. m6A modification-mediated BATF2
 445 suppresses metastasis and angiogenesis of tongue squamous cell carcinoma through
 446 inhibiting VEGFA. *Cell Cycle* 2023; 22: 100-116.
 447 <https://doi.org/10.1080/15384101.2022.2109897>
- 448 [50] LIU Z, WEI P, YANG Y, CUI W, CAO B et al. BATF2 Deficiency Promotes Progression in
 449 Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for
 450 Combining MET Inhibitors with IFNs. *Clin Cancer Res* 2015; 21: 1752-1763.
 451 <https://doi.org/10.1158/1078-0432.Ccr-14-1564>
- 452 [51] LI Y, FAN L, YAN A, REN X, ZHAO Y et al. Exosomal miR-361-3p promotes the viability
 453 of breast cancer cells by targeting ETV7 and BATF2 to upregulate the PAI-1/ERK pathway.
 454 *J Transl Med* 2024; 22: 112. <https://doi.org/10.1186/s12967-024-04914-4>

- [52] ZONG Y, CHANG Y, HUANG K, LIU J, ZHAO Y. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy. *Int Immunopharmacol* 2024; 126: 111199. <https://doi.org/10.1016/j.intimp.2023.111199>
- [53] CAO L, WENG K, LI L, LIN G, ZHAO Y et al. BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/ β -catenin pathway. *Theranostics* 2024; 14: 7007-7022. <https://doi.org/10.7150/thno.98389>
- [54] WEBER AM, RYAN AJ. ATM and ATR as therapeutic targets in cancer. *Pharmacol Ther* 2015; 149: 124-138. <https://doi.org/10.1016/j.pharmthera.2014.12.001>
- [55] HUANG C, FILIPPONE NR, REINER T, ROBERTS S. Sensors and Inhibitors for the Detection of Ataxia Telangiectasia Mutated (ATM) Protein Kinase. *Mol Pharm* 2021; 18: 2470-2481. <https://doi.org/10.1021/acs.molpharmaceut.1c00166>
- [56] JIANG Q, CHEN Z, MENG F, ZHANG H, CHEN H et al. CD36-BATF2/MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer. *Int J Biol Sci* 2023; 19: 4476-4492. <https://doi.org/10.7150/ijbs.87635>
- [57] LI BY, LI HL, ZENG FE, LUAN XY, LIU BQ et al. Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy. *Discov Oncol* 2025; 16: 689. <https://doi.org/10.1007/s12672-025-02515-1>

Figure Legends

Figure 1. BATF2 mediates chemosensitivity of NCI-N87 cells to ADR and VCR. A) protein expression of BATF2 in different cells determined by Western blot; B) mRNA expression of BATF2 after overexpression or inhibition in two drug-resistant cells; C) CCK-8 assay for determining the cell viability after BATF2 overexpression or inhibition; D) representative images of flow cytometry for analyzing cell apoptosis after BATF2 overexpression or inhibition; E) Quantification of cells apoptosis determined by flow cytometry. * $p < 0.05$, ** $p < 0.01$

Figure 2. BATF2 regulates KIFC1 expression and centrosome clustering. A) protein bands (upper) and quantification (lower) of KIFC1 in two drug-resistant cells after BATF2 overexpression or inhibition; B) representative immunofluorescence images (left) and corresponding quantification (right) of the proportion of cells with centrosome cluster after BATF2 overexpression or inhibition. * $p < 0.05$, ** $p < 0.01$

Figure 3. BATF2 mediates ATM phosphorylation in drug-resistant cells. A) level of p-ATM/ATM in NCI-N87 cells and drug-resistant NCI-N87 cells determined by Western blot; B) Western blot bands

491 of Co-IP for investigating the interactions between BATF2 and ATM; C) levels of p-ATM/ATM
492 after BATF2 overexpression or inhibition. * $p < 0.05$, ** $p < 0.01$

493

494 **Figure 4.** BATF2 promotes chemosensitivity by inhibiting ATM phosphorylation. A) protein bands
495 and quantification of BATF2, ATM and p-ATM expression in each group; B) cell viability of cells
496 in each treatment group determined by CCK-8 assay; C, representative images (left) and
497 corresponding quantification (right) of flow cytometry for analyzing cell apoptosis in each
498 treatment group. * $p < 0.05$, ** $p < 0.01$

499

500 **Figure 5.** BATF2 restrains centrosome clustering by inhibiting ATM phosphorylation. A) protein
501 bands (upper) and quantification (lower) of KIFC1 expression in two drug-resistant cells in each
502 group; B) representative immunofluorescence images (left) and corresponding quantification (right)
503 of the proportion of cells with centrosome cluster in each group. * $p < 0.05$, ** $p < 0.01$

504

505 **Figure 6.** ATM inhibitor reverses the effects of BATF2 knockdown on cells viability and apoptosis.
506 A) protein bands and quantification of ATM and p-ATM expression in each group; B) cell viability
507 of cells in each treatment group determined by CCK-8 assay; C) representative images (left) and
508 corresponding quantification (right) of flow cytometry for analyzing cell apoptosis in each
509 treatment group. * $p < 0.05$, ** $p < 0.01$

510

511 **Figure 7.** Overview of the mechanism under BATF2-mediated MDR in GC.

Fig. 1 [Download full resolution image](#)




Fig. 2 [Download full resolution image](#)




Fig. 3 [Download full resolution image](#)




Fig. 4 [Download full resolution image](#)




Fig. 5 [Download full resolution image](#)




Fig. 6 [Download full resolution image](#)




Fig. 7 [Download full resolution image](#)

